Dr Reddy's Laboratories Ltd. saw an 86% YoY (year-on-year) plunge in its consolidated net profit for the fiancial results for the fourth quarter of fiscal 2025-26, according to an exchange filing from the company on Monday. The company declared a dividend of Rs 8 per share. The record date for determining the eligibility of the shareholders is July 10.
The company's net profit was At Rs 221 crore from Rs 1,593 crore in the year-ago period. The firm's net profit missed Bloomberg analyst's estimates of Rs 871 crore. The firm suffered impact from a Shelf Stock Adjustment ('SSA') related to lenalidomide of Rs 4,530 crore It also dealt with impairment of CAR-T assets and Eftilagimod Alfa of a total of Rs 27 crore and provisions related to VAT (value added tax) liability of Rs 14 crore.
ALSO READ: Dixon Tech Q4 Results: Profit Sinks 36%, Dividend Declared; Check Record Date
The firm's revenue decreased 12% YoY to Rs 7,546 crore from Rs 8,528 crore in the year-ago period. Bloomberg analysts' estimates were at Rs 8,248 crore. The company's Ebitda (earnings before interest, taxes, depreciation) and amortisation was 60% lower to Rs 981 crore from Rs 2,475 crore in the preceding fiscal. Bloomberg analysts' estimates were at Rs 1,507 crore.
The firm's Ebitda margin contracted to 13% YoY from 29% in the year prior. Bloomberg analysts' estimates were at 18.3%.
Dr Reddy's Laboratories Q4 Results Highlights
- Net Profit down 86.1% At Rs 221 crore Vs Rs 1,593 crore
- Revenue down 11.5% At `7,546 Cr Vs `8,528 Cr YoY
- Ebitda down 60.4% At `981 Cr Vs `2,475 YoY
- Ebitda Margin At 13% Vs 29.1% YoY
Share price of Dr Reddy's Laboratories saw a 0.77% downturn to trade at Rs 1,270 per share at the end of the day's trade, compared to a 1.83% decline of the NSE Nifty 50.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
.png?im=FeatureCrop,algorithm=dnn,width=350,height=197)
